Ultragenyx Pharma (RARE) PT Lowered to $70 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $16.55 -0.48%
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Wedbush analyst Laura Chico lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $70.00 (from $72.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Ultragenyx Pharma (RARE) PT Raised to $19 at TD Cowen
- Red Rock Resorts (RRR) PT Lowered to $60 at StoneX
- Ultragenyx Pharma (RARE) PT Raised to $19 at Wells Fargo
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
